Pharma-backed TransCelerate makes progress on clinical trial efficiency
This article was originally published in SRA
TransCelerate BioPharma, the non-profit organization founded by 10 big pharma companies to quickly address issues that hamper clinical trial efficiency, has taken swift action on all five of the objectives the group outlined in 2012 when it was first established. In addition, the group has adopted a list of five new priorities.
You may also be interested in...
Efficient development and review is being hindered by the inability to exchange data freely and truly capitalize on the digital age, CDER director says, challenging industry, regulators and others to creatively think about how to move away from legacy, paper-based processes in clinical trials and regulatory submissions.
Private Company Edition: With its lead program in the clinic, Frontier’s $80m series C round will fund trials for additional programs. Also, ORI raises $260m for second fund, Earlybird closed a €173m ($187.1m) fund, Areteia’s series A grew to $425m and Sudo’s series B increased to $147m.
Zelnecirnon (RPT193), in Phase IIb for atopic dermatitis and Phase IIa for asthma, may not have caused the case of liver failure cited in the hold but the pause may impede a crucial data readout.